Cargando…
Antiepileptogenesis and disease modification: Progress, challenges, and the path forward—Report of the Preclinical Working Group of the 2018 NINDS‐sponsored antiepileptogenesis and disease modification workshop
Epilepsy is one of the most common chronic brain diseases and is often associated with cognitive, behavioral, or other medical conditions. The need for therapies that would prevent, ameliorate, or cure epilepsy and the attendant comorbidities is a priority for both epilepsy research and public healt...
Autores principales: | Galanopoulou, Aristea S., Löscher, Wolfgang, Lubbers, Laura, O’Brien, Terence J., Staley, Kevin, Vezzani, Annamaria, D’Ambrosio, Raimondo, White, H. Steve, Sontheimer, Harald, Wolf, John A., Twyman, Roy, Whittemore, Vicky, Wilcox, Karen S., Klein, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166793/ https://www.ncbi.nlm.nih.gov/pubmed/34033232 http://dx.doi.org/10.1002/epi4.12490 |
Ejemplares similares
-
Antiepileptogenesis and disease modification: Clinical and regulatory issues
por: French, Jacqueline A., et al.
Publicado: (2021) -
Selected Molecular Targets for Antiepileptogenesis
por: Pawlik, Marek J., et al.
Publicado: (2021) -
Development of an antiepileptogenesis drug screening platform: Effects of everolimus and phenobarbital
por: Barker‐Haliski, Melissa, et al.
Publicado: (2021) -
Preclinical common data elements (CDEs) for epilepsy: A joint ILAE/AES and NINDS translational initiative
por: Scharfman, Helen E., et al.
Publicado: (2018) -
Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate
por: Koepp, Matthias J., et al.
Publicado: (2023)